08:26 AM EST, 12/17/2024 (MT Newswires) -- Tenaya Therapeutics ( TNYA ) said Tuesday that preliminary data from the first cohort of three patients in a phase 1b/2 trial showed that its TN-201 gene therapy was well tolerated, with no cardiac toxicities or severe adverse effects.

TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic cardiomyopathy, a condition caused by insufficient levels of myosin-binding protein C, the company said.

Tenaya said the initial results demonstrated "readily detectable vector DNA in the heart, evidence of transgene RNA expression, and increasing TN-201 mRNA and MyBP-C protein levels over time."

Tenaya Therapeutics ( TNYA ) shares were down 12% in recent premarket trading.